Cannabigerol (CBG) Attenuates Mechanical Hypersensitivity Elicited by Chemotherapy-Induced Peripheral Neuropathy."

Background. Cannabigerol (CBG) is a non-psychoactive phytocannabinoid produced by the plant Cannabis sativa with affinity to various receptors involved in nociception. As a result, CBG is marketed as an over-the-counter treatment for many forms of pain. However, there is very little research-based evidence for the efficacy of CBG as an anti-nociceptive agent. Methods. To begin to fill this knowledge gap, we assessed the anti-nociceptive effects of CBG in C57BL/6 mice using three different models of pain; cisplatin-induced peripheral neuropathy, the formalin test, and the tail-flick assay. Results. Using the von Frey test, we found that CBG attenuated mechanical hypersensitivity evoked by cisplatin-induced peripheral neuropathy in both male and female mice. Additionally, we observed that this CBG-induced reduction in mechanical hypersensitivity was attenuated by the 2-adrenergic receptor antagonist atipamezole (3 mg/kg, i.p.) and the CB1R antagonist, AM4113 (3 mg/kg, i.p.), and blocked by the CB2R antagonist/inverse agonist, SR144528 (10 mg/kg, i.p.). We found that the TRPV1 antagonist, SB705498 (20 mg/kg, i.p.) was unable to prevent CBG actions. Furthermore, we show that CBG:CBD oil (10 mg/kg, i.p.) was more effective than pure CBG (10 mg/kg) at reducing mechanical hypersensitivity in neuropathic mice. Lastly, we show that pure CBG and CBG:CBD oil were ineffective at reducing nociception in other models of pain, including the formalin and tail flick assays. Conclusions. Our findings support the role of CBG in alleviating mechanical hypersensitivity evoked by cisplatin-induced peripheral neuropathy, but highlight that these effects may be limited to specific types of pain.

Files

Metadata

Work Title Cannabigerol (CBG) Attenuates Mechanical Hypersensitivity Elicited by Chemotherapy-Induced Peripheral Neuropathy."
Access
Open Access
Creators
  1. Nicholas Graziane
License In Copyright (Rights Reserved)
Work Type Article
Publisher
  1. Wiley
Publication Date July 28, 2022
Publisher Identifier (DOI)
  1. https://doi.org/10.1002/ejp.2016
Deposited April 08, 2025

Versions

Analytics

Collections

This resource is currently not in any collection.

Work History

Version 1
published

  • Created

    April 08, 2025 08:53 by nzg66

  • Updated

    April 08, 2025 08:53 by [unknown user]

  • Updated Description, Publication Date Show Changes

    April 08, 2025 08:55 by nzg66

    Description
    • Background. Cannabigerol (CBG) is a non-psychoactive phytocannabinoid produced by the plant Cannabis sativa with affinity to various receptors involved in nociception. As a result, CBG is marketed as an over-the-counter treatment for many forms of pain. However, there is very little research-based evidence for the efficacy of CBG as an anti-nociceptive agent.
    • Methods. To begin to fill this knowledge gap, we assessed the anti-nociceptive effects of CBG in C57BL/6 mice using three different models of pain; cisplatin-induced peripheral neuropathy, the formalin test, and the tail-flick assay.
    • Results. Using the von Frey test, we found that CBG attenuated mechanical hypersensitivity evoked by cisplatin-induced peripheral neuropathy in both male and female mice. Additionally, we observed that this CBG-induced reduction in mechanical hypersensitivity was attenuated by the 2-adrenergic receptor antagonist atipamezole (3 mg/kg, i.p.) and the CB1R antagonist, AM4113 (3 mg/kg, i.p.), and blocked by the CB2R antagonist/inverse agonist, SR144528 (10 mg/kg, i.p.). We found that the TRPV1 antagonist, SB705498 (20 mg/kg, i.p.) was unable to prevent CBG actions. Furthermore, we show that CBG:CBD oil (10 mg/kg, i.p.) was more effective than pure CBG (10 mg/kg) at reducing mechanical hypersensitivity in neuropathic mice. Lastly, we show that pure CBG and CBG:CBD oil were ineffective at reducing nociception in other models of pain, including the formalin and tail flick assays.
    • Conclusions. Our findings support the role of CBG in alleviating mechanical hypersensitivity evoked by cisplatin-induced peripheral neuropathy, but highlight that these effects may be limited to specific types of pain.
    Publication Date
    • 2022-07-28
  • Added Creator Nicholas Graziane

    April 08, 2025 08:56 by nzg66

  • Added 2022-sepulveda-CBG-V7.docx

    April 08, 2025 08:56 by nzg66

  • Updated Publisher, Publisher Identifier (DOI), License Show Changes

    April 08, 2025 09:04 by nzg66

    Publisher
    • Wiley
    Publisher Identifier (DOI)
    • https://doi.org/10.1002/ejp.2016
    License
    • https://rightsstatements.org/page/InC/1.0/
  • Published

    April 08, 2025 09:04 by nzg66

  • Updated

    April 08, 2025 22:04 by [unknown user]